TG1101-RMS404 - A Post-Authorization Study to Characterize the Safety of BRIUMVI (ublituximab) Use in Pregnant Patients with Multiple Sclerosis Using Data from a US Administrative Healthcare Claims Database

Data sources

• Data source(s), other:
  MarketScan data
• Data sources (types):
  Drug registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown